Home Recros Medica Inc.

Recros Medica Inc.

5/8/19: FDA Accepts Recros Medica De Novo Submission for Nuvellus ™ Focal Contouring System

Recros Medica, Inc. announced today that its de novo regulatory submission for the Nuvellus™ Focal Contouring System has been accepted for review by the US Food and Drug Administration (FDA). Nuvellus utilizes the company's proprietary Rotational Fractional Resection (RFR) technology and may provide medical aesthetic physicians a minimally-invasive single treatment option to improve submental (neck and jowl) contouring.